Skip to main content


Log in

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

  • Published:
Investigational New Drugs Aims and scope Submit manuscript


Objective The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas. Methods Cohorts of four patients with metastatic soft tissue sarcomas received up to five cycles of intravenous ifosfamide 3000 mg/m2 on days 1– 3 in combination with escalating doses of intravenous Myocet on day 1 every 3 weeks until dose limiting toxicity (DLT) in at least one patient. Starting dose of Myocet was 40 mg/m2 to be escalated through 10 mg/m2 increase up to 80 mg/m2. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria v3.0 (NCI-CTC v3.0). Results Ten patients were enrolled in the study and 8 of them received the treatment. Median age was 45 years, 3 patients were male and 5 were female. DLT, consisting of neutropenic fever, was reached in one patient at dose level 2 (Myocet 50 mg/m2). Therefore, the MTD and the recommended phase II dose is 40 mg/m2. Conclusions The combination of intravenous Myocet 40 mg/m2 on day 1 and ifosfamide 3,000 mg/m2 on days 1–3 every 3 weeks is safe and feasible; a phase II study is ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Nielsen OS, Blay JY, Judson IR et al (2003) Metastatic soft tissue sarcoma in adults: prognosis and treatment options. Am J Cancer 2:211–21

    Article  CAS  Google Scholar 

  2. Verweij J, Mouridsen HT, Nielsen OS et al (1995) The present state of art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Critical Rev Oncol/Hematol 20:193–201

    Article  CAS  Google Scholar 

  3. Mocellin S, Rossi CR, Brandes A, Nitti D (2006) Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 32:9–27

    Article  CAS  PubMed  Google Scholar 

  4. Launchbury AP, Habboubit N (1993) Epirubicin and doxorubicin: a comparison of their characteristics, therapeuthic activity and toxicity. Cancer Treatm Rev 19:197–228

    Article  CAS  Google Scholar 

  5. Antman K, Crowley J, Balcerzak SP et al (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276–85

    CAS  PubMed  Google Scholar 

  6. Grosso F, Jones RL, Demetri GD et al (2007) Efficacy of trabectedin (ecteinascidin - 743) in advanced pretreated myxoid liposarcoma: a retrospective study. Lancet Oncol 8:595–602

    Article  CAS  PubMed  Google Scholar 

  7. Shöffski P, Dumez H, Wolter P et al (2008) Clinical impact of trabectedin (ecteinascidin - 743) in advanced / metastatic soft tissue sarcoma. Expert Opin Pharmacother 9:1609–18

    Article  Google Scholar 

  8. Edmonson JH, Ryan LM, Blum RH et al (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269–75

    CAS  PubMed  Google Scholar 

  9. Santoro A, Tursz T, Mouridsen H et al (1993) Doxorubicin versus cyvadic versus doxurubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537–45

    Google Scholar 

  10. Bramwell VHC, Mouridsen HT, Mulder JH, et al (1983) Carminomycin vs. adriamycin in advanced soft tissue sarcomas: an EORTC randomized phase II study. Eur J Cancer Clin Oncol 19:1097–104

    Google Scholar 

  11. Bull FE, von Hoff DD, Balcerak SP et al (2000) Phase II trial of mitoxantrone in advanced sarcomas: a Southwest oncology group study. Cancer Treat Reports 69:231–3

    Google Scholar 

  12. Nielsen OS, Dombernowsky P, Mouridsen H, et al (2000) Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group. Sarcoma 4:31–5

    Google Scholar 

  13. Gianni L, Herman EH, Lipshultz SE et al (2008) Anthracycline cardiotoxicity : from bench to bedside. J Clin Oncol 26:3777–84

    Article  PubMed  Google Scholar 

  14. Safra T: Cardiac safety of liposomal anthracyclines. The Oncologist, 8(s): 17–24, 2003.

    Google Scholar 

  15. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–78

    Article  CAS  PubMed  Google Scholar 

  16. Batist G, Ramakrishnan G, Rao CS et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:3439–41

    Google Scholar 

  17. Cowens JW, Creaven PJ, Greco WR et al (1993) Initial clinical (phase I) trial of MYOCET (doxorubicin encapsulated in liposomes). Cancer Res 53:2796–802

    CAS  PubMed  Google Scholar 

  18. Valero V, Buzdar AU, Theriault RL et al (1999) Phase II trial of Liposome-Encapsulated doxorubicin, Cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17:1425–34

    CAS  PubMed  Google Scholar 

  19. Shapiro CL, Ervin T, Welles L et al (1999) Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncol 17:1435–41

    CAS  PubMed  Google Scholar 

  20. Chan S, Davidson N, Juozaityte E et al (2004) Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 15:1527–34

    Article  CAS  PubMed  Google Scholar 

  21. Mross K, Niemann B, Massin U et al (2004) Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors : an open label, single dose study. Cancer Chemother Pharmacol 54:514–524

    Article  CAS  PubMed  Google Scholar 

  22. Swenson CE, Bolcsak LE, Batist G, et al (2003) Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome- encepsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs, 14: 239–246

    Google Scholar 

  23. Allen TM, Martin FJ (2004) Advantages of liposomal delivery systems for anthracyclines. Semin Oncol, 31(6 Suppl 13):5–15

    Google Scholar 

  24. Torti FM, Bristow MF, Howes AE et al (1984) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule, assessment by endomyocardial biopsy. Ann Intern Med 99:745–749

    Google Scholar 

  25. Ewer MS, Ali MK, Mackay B et al (1984) A comparison of cardiac biopsy grades and ejection fraction estimation in patients receiving Adriamycin. J Clin Oncol 5:112–117

    Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Elisa Stroppa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stroppa, E., Bertuzzi, A., Di Comite, G. et al. Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. Invest New Drugs 28, 834–838 (2010).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: